Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
0(0%)
Results Posted
22%(2 trials)

Phase Distribution

Ph phase_1
4
44%
Ph phase_2
5
56%

Phase Distribution

4

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
5(55.6%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(9)

Detailed Status

Completed9

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (44.4%)
Phase 25 (55.6%)

Trials by Status

completed9100%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_2

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

NCT01894516
completedphase_2

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
completedphase_2

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

NCT02048618
completedphase_1

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

NCT02084199
completedphase_2

Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

NCT01668641
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT01894516Phase 2

Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)

Completed
NCT01888874Phase 2

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

Completed
NCT02048618Phase 2

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Completed
NCT02084199Phase 1

Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects

Completed
NCT01668641Phase 2

Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Completed
NCT01798979Phase 1

A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects

Completed
NCT01384422Phase 2

Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients

Completed
NCT01419990Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy Subjects

Completed
NCT01179581Phase 1

First-in-Human Single Ascending and Multiple Dose of GLPG0634

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9